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Abstract 
In the last decade TTCC have been unveiled as key regulators of cancer cells biology and thus have been 
proposed as chemotherapeutic targets. Indeed in vitro and in vivo studies indicate that TTCC 
pharmacological blockers have a negative impact on the viability of cancer cells and reduce tumor size, 
respectively. Consequently mibefradil, a TTCC blocker approved in 1997 as an antihypertensive agent but 
withdrawn in 1998 because of drug-drug interactions, was granted 10 years later the orphan drug status by 
the FDA to investigate its efficacy against brain, ovary and pancreatic cancer. However, the existence of 
different channel isoforms with distinct physiological roles, together with the lack of selective 
pharmacological agents, has hindered a conclusive chemotherapeutic evaluation. Here we review the 
available evidence on TTCC expression, value as prognostic markers and effectiveness of their 
pharmacological blockade on cancer cells in vitro and in preclinical models. We additionally summarize the 
status of clinical trials using mibefradil against glioblastoma multiforme. Finally, we discuss the future 
perspectives and the importance of further development of multidisciplinary research efforts on the 
consideration of TTCC as biomarkers or targetable molecules in cancer. 
 
Introduction 
T-type Ca2+ channels  (TTCC) were first reported by Hagiwara and colleagues in the 1970s in voltage-
clamped starfish eggs (1). These channels could be distinguished from other voltage-gated Ca2+ channels 
(VGCC) on the basis of their fast activation and inactivation at negative potentials and slow deactivation 
kinetics. Because of these peculiarities and small single channel conductance, they were later coined as T-
type Ca2+ channels (T for transient and tiny, TTCC) or low voltage-activated (LVA) channels, in contrast with 
the high voltage-activated channels (HVA) comprising the rest of VGCC families. It took quite a few years 
before the molecular cloning of the first member of the TTCC family, 1G (2), termed Cav3.1 by the 
nomenclature established in 2000 (3). This was shortly followed by the molecular identification of the two 
other members of TTCC, 1H (Cav3.2)(4) and 1I (Cav3.3)(5).  
TTCC were initially linked to membrane excitability, such as cardiac pacemaker potentials (6) and neuron 
oscillatory firing (7)(8). TTCC are present in central and peripheral neurons, and abnormalities in their 
expression or function have been linked to a range of neurological diseases, including absence seizures, 
epilepsies and neuropathic pain (9)(10). Nonetheless, TTCC provide a key pathway for Ca2+ entry in non-
excitable cells, and eventually their expression was found to be enhanced during the G1/S transition in 
proliferating cells (11)(12).  
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G1 to S phase transition requires Ca2+ influx through multiple Ca2+ channels at the plasma membrane (13). 
As cells re-enter the cell cycle in early G1, Ca2+ elevations promote the activation of AP-1 (Fos/Jun), cAMP-
responsive element binding, and nuclear factor of activated T-cell (NFAT) transcription factors, which 
control the expression, assembly or stability of cyclin/cyclin dependent kinase (CDK) complexes essential 
for progression to the S phase (14) (Fig. 1).  
The contribution of TTCC to cell cycle control is based on their distinct biophysical properties. From a 
closed-deactivated state, TTCC activate by weak membrane depolarization, which is rapidly followed by 
adoption of a closed-inactivated (refractory) state. At the steady-state, overlap between activation and 
inactivation potential ranges leaves a small fraction of TTCC open, enabling sustained inward Ca2+ currents 
(termed window currents) that may regulate Ca2+-sensitive processes (15)(16). Membrane potential (Vm) is 
a key regulator of cell cycle and is subject to fluctuations in proliferating cells (17). Of note, Vm is 
hyperpolarized in the G1 and S phases, corresponding to the activation or increased expression of different 
K+ channels, including Ca2+-activated K+ (K(Ca2+)) channels which form functional tandems with TTCC 
(7)(15). G1/S hyperpolarization could lead to increased Ca2+ window currents, or TTCC availability, 
especially in cells with more depolarized mean Vm, such as stem or cancer cells. The involvement of TTCC in 
cell cycle progression promoted by growth factors was modelled by Gray and colleagues (12): production of 
inositol triphosphate triggers Ca2+ release from the endoplasmic reticulum (ER), activating K(Ca2+) channels. 
The ensuing membrane hyperpolarization removes TTCC inactivation, facilitating a Ca2+ influx that, upon 
Ca2+ binding to S100 proteins, inhibits the p53/p21 pathway to pass the G1/S restriction point. However, 
the signaling mechanisms that control cell cycle downstream of TTCC-mediated Ca2+ entry do not appear to 
be limited to p53 inactivation. Proven transducers of TTCC activity are calmodulin (CaM)and downstream 
effector calmodulin kinase II (CaMKII) (18). Activation of Cav3.1 heterologously expressed in HEK293 cells 
has been shown to transiently activate the Ras/MEK/extracellular signal-regulated kinase (ERK) pathway 
(19), whereas TTCC blockade inhibits the PKB/Akt pathway in GBM, being both signaling routes involved in 
G1/S progression (20). It is also known that Cav3.2 regulates the calcineurin (CaN)/NFAT pathway through 
both Ca2+ entry and direct binding to CaN, to induce cardiac hypertrophy (21). In addition, Ca2+ influx via 
Cav3.2 regulates the expression of the Sox9 transcription factor by CaN/NFAT activation during tracheal 
chondrogenesis (22). Furthermore, Cav3.1-deficient T helper cells showed a reduced nuclear translocation 
of NFAT, in turn leading to a decreased secretion of Granulocyte-macrophage colony-stimulating factor and 
unveiling a role for TTCC in lymphocyte differentiation (23). Thus and notwithstanding the proven role of 
TTCC in G1/S progression, the expression of TTCC can also be associated to cell cycle exit (Fig.1).  
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TTCC as prognostic markers in cancer  
Increased basal Ca2+ influx and remodeled Ca2+ signaling pathways may contribute to tumor progression by 
enhancing proliferation, promoting invasiveness and conferring chemotherapeutic resistance (24)(25). 
Hence, important questions are whether TTCC are differentially expressed in cancer cells, and if the TTCC 
signature has prognostic value. 
Available data indicates that TTCC expression levels depend on cancer type, stage and TTCC isoform (Table 
1). Immunohistochemical staining (IHC) showed that both Cav3.1 and Cav3.2 expression were increased in 
tumoral vs normal ovarian tissue (26). According to Human Protein Atlas, 82% of glioblastoma multiforme 
(GBM) biopsies expressed Cav3.1 and 27% expressed Cav3.2. The same database indicates that all prostate 
cancer samples expressed Cav3.2, while 75% expressed Cav3.1. The expression of Cav3.3 was not 
determined (27). Maiques and colleagues performed IHC against TTCC comparing normal skin, melanocytic 
nevi and different types of melanoma (28). TTCC immunoexpression increased gradually from normal skin 
to common naevi, dysplastic naevi and melanoma samples, with differences in the distribution of isoforms. 
Particularly, Cav3.2 was highly expressed in metastatic compared to primary melanoma. Positive 
correlations were found between Cav3.2, proliferative and hypoxia markers, and between Cav3.1, 
autophagy markers and the BRAFV600E mutation. Furthermore, Cav3.2 transcripts and protein were highly 
expressed in a subset of GBM tumors enriched in glioma stem cells (GSC) (20), consistent with a previously 
described role for this isoform in stemness (29). However, the expression of the Cav3.1 isoform, which was 
previously shown at the mRNA level in a vast array of GSC lines (30), was not investigated.  
Nonetheless, both up- and down-regulation of TTCC can become cancer’s molecular signature. Phan and 
colleagues performed a bioinformatics analysis on the expression of TTCC transcripts in >4000 cancer tissue 
samples by accessing Oncomine, a microarray database (31). The three TTCC isoforms exhibited variable 
levels in several cancer subtypes, including over- and under-expression when compared to normal tissues 
(Table 1).  
The prognostic relevance of the TTCC gene signature in cancer is a crucial question. An in silico genomic 
analysis of The Cancer Genome Atlas (TCGA) database revealed that disease-free and overall survival 
correlated inversely with expression of Cav3.1 and Cav3.2 in melanoma (28). Another study using the TCGA 
database revealed alterations of the Cav3.2 gene in 15/136 GBM samples, and these cases presented a 
trend towards shorter overall survival (20). 
Querying the Kaplan-Meier plotter database, Fornaro and colleagues performed a correlation study 
between TTCC expression in solid tumors and patient survival. In gastric cancer patients, the expression of 
Cav3.1 was associated to an extended overall survival, whereas Cav3.2 (best single predictor) and Cav3.3 
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were associated with poorer outcomes. This trend was repeated for lung cancer, while in ovarian cancer 
patients Cav3.1 and Cav3.2 swapped the sign of their correlations with overall survival (32).  
Thus, overexpression of specific TTCC isoforms appears to have a protective effect on specific cancer types 
and stages. Conversely, DNA aberrant methylation of the CACNA1G gene (encoding Cav3.1 channels) has 
been found in 18-35% of different human primary tumors, including pancreatic (33), hepatic (34), gastric, 
colorectal and acute myelogenous leukemia (35)(36). The promoter region of CACNA1G is a target for the 
CpG island methylator phenotype, which implies the inactivation of multiple tumor suppressor genes 
(35)(36). The inactivation of CACNA1G may play a role in cancer development by favoring proliferation 
and/or avoiding apoptotic or autophagic pathways, but few studies have addressed these questions (Table 
1). 
 
Effects of TTCC blockade/gene silencing in cancer cells: in vitro studies 
The expression of TTCC in cancer cells was first reported in retinoblastoma Y79 cells shortly after their 
molecular identification (37). The notion that it was possible to halt cancer cell proliferation or induce 
cancer cell death by inhibiting TTCC, was built up in the following years through in vitro studies on a wide 
range of cancer cells.    
 
Reduced Proliferation 
Numerous studies have shown that TTCC pharmacological blockade or gene silencing reduce the 
proliferation of cancer cells (12)(38). However, only a few provided insights on the pathways triggered by 
TTCC blockade/silencing. Lu and colleagues reported that pharmacological inhibition of TTCC with 
mibefradil reduced cell proliferation via p53-dependent upregulation of CDK inhibitor p21 (39), halting 
G1/S progression (Fig.1). Further, mibefradil-induced activation of the p38-mitogen activated kinase 
(MAPK) pathway caused p53 accumulation, resulting in cell cycle arrest (and death) of colon cancer cells 
(40).  
 
Inhibition of neuroendocrine differentiation 
Unlike most cancer types, neuroblastoma can undergo a spontaneous complete regression through 
neuronal-like differentiation (41). Chemin and colleagues demonstrated that either pharmacological 
blockade of TTCC or interfering with the expression of Cav3.2 (using antisense nucleotides) prevented 
cAMP-induced neuritogenesis of neuroblastoma-glioma NG108-15 cells and HVA Ca2+ channel expression, 
indicating a dual role of TTCC in promoting morphological changes and membrane excitability at early 
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stages of neuronal differentiation (42). Moreover, H2S- induced differentiation of NG108-15 cells involved 
the phosphorylation of Src kinase and was abolished by ascorbic acid (a proven inhibitor of Cav3.2) and by 
mibefradil (43). Other than Src activation, Chemin and colleagues found that Ca2+ influx through TTCC 
promotes neuroblastoma differentiation by an autocrine mechanism (44).  
Cav3.2 channels also proved to be relevant for neuroendocrine differentiation of human prostate cancer 
cells (45)(46)(47). During this process, prostate cancer cells develop neurite-like processes and secrete 
diverse mitogenic factors with paracrine or autocrine actions (47). Opposite to neuroblastoma, 
differentiation of prostate epithelial cells is associated with an increased aggressiveness of prostate 
tumors, adoption of an androgen-refractory phenotype and poor prognosis (48). Two recent works 
confirmed the mediation of Cav3.2 channels in the differentiation of prostate cancer LNCaP cells subject to 
physiologically relevant stimuli: sodium butyrate increased the expression of Cav3.2 channels at the mRNA 
and protein level, and their pharmacological blockade decreased the number and length of neurite-like 
processes and cell viability (46). The same research group showed that interleukin-6 up-regulated Cav3.2 
channels by a posttranscriptional mechanism. Again, pharmacological blockade of TTCCs limited neurite 
number and extension (47).  
 
Decreased cell survival 
2013 was a turning point in the consideration of the physiological roles of TTCC in cancer cells. Dzigielewska 
and colleagues reported a dual effect of mibefradil on reducing proliferation and inducing caspase-
dependent apoptosis of colon cancer cells, by p38-MAPK activation and p53 upregulation (40). Our 
research group proved that the structurally unrelated TTCC blockers mibefradil and pimozide halt 
melanoma cell proliferation at the G1/S transition and induce the intrinsic apoptosis pathway with 
activation of caspases-3 and -9 (49). Death occurred after induction of the unfolded protein response to ER 
stress, followed by subsequent blockade of constitutive autophagy. siRNA-mediated silencing of Cav3.1 and 
Cav3.2 isoforms exerted similar effects, demonstrating that TTCC play a role in Ca
2+ homeostasis 
maintenance and in sustaining basal macroautophagy. The sequence of events linking TTCC 
blockade/silencing and autophagy deregulation has only been partially elucidated. Huang and colleagues 
showed that mibefradil and its derivative NNC-55-0396 exerted a dual role on leukemia cells viability, by 
promoting both G1/S arrest and apoptosis, that was preceded by ER Ca2+-release and depolarization of the 
mitochondrial membrane (50). Earlier this year, Niklasson et al. performed a drug screening assay on GSC 
and found that, among different disruptors of Ca2+ signaling network, TTCC and K(Ca2+) channel blockers 
decreased their viability (30). Transcriptomics and proteomics analyses revealed that, upon channel 
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blockade, the GSC plasma membrane depolarized, intracellular Na+ increased and Na+-dependent transport 
was reduced, leading to nutrient starvation and cell death.  
Nutrient starvation is a stimulus for macroautophagy by activating AMP-activated protein kinase and/or 
inhibiting the mTOR complex (51). Accordingly, KYS05090, a dihydroquinazoline with TTCC-blocking 
properties, induced autophagy and apoptosis in lung carcinoma A549 cells through reactive oxygen species  
generation and subsequent inhibition of glucose uptake (52). Nevertheless, autophagy deregulation by 
TTCC inhibition appears to be double edged. It is known that Ca2+ is required for phagosome-lysosome 
function (53); in this scenario, it is tempting to speculate that TTCC inhibition could prevent the influx of 
Ca2+ necessary for autophagolysosomal formation, de facto blocking macroautophagy at a late step, as 
observed for the effects of mibefradil in melanoma cells (49).  
TTCC blockade/knockdown can also lead to apoptosis by inactivating Ca2+ signaling pathways relevant for 
cell survival. Valerie and colleagues showed that, in addition of inhibiting proliferation, mibefradil or siRNA-
mediated Cav3.1/Cav3.2 gene silencing induced the apoptotic death of GBM cells through 
dephosphorylation of pro-survival Akt and cleavage of caspase-3 and -7 (54). This pathway can also be 
triggered in ovarian cancer cells, resulting in reduced levels of anti-apoptotic survivin (55). Remarkably, 
these works demonstrated that TTCC inhibition also sensitizes cancer cells to the chemotherapeutic of 
choice (temozolomide for GBM and carboplatin for ovarian cancer), thus establishing the grounds for the 
use of TTCC blockers in combined therapies. 
Similarly, Zhang and colleagues have recently shown that mibefradil treatment reduced the viability of GSC, 
partly due to inhibition of pro-survival Akt/mTOR pathways and upregulation of p27 and BAX proteins (20). 
A further RNA-seq transcriptomic analyses on GSC found that mibefradil attenuated the expression of 
several oncogenes and promoted the expression of different tumor suppressor genes, proving that the 
signaling pathways stemming from TTCC blockade can be complex and intricate. 
Together, these works indicate that the role of TTCC spans beyond the control of cancer cell cycle into the 
regulation of cancer cell homeostasis, such that their pharmacological blockade or gene silencing 
deregulates Ca2+ dependent physiological processes pivotal for cell survival (Fig. 2). 
 
Effects of TTCC blockade/gene silencing on tumor growth: in vivo studies  
While TTCC blockade/gene silencing has shown to decrease the viability of cancer cells in vitro, albeit with 
notable exceptions regarding Cav3.1 knockdown, these strategies needed validation in preclinical models 
before consideration of TTCC targeting in clinical assays. 3D tumor growth implies a hypoxic 
microenvironment and altered focal/cell-cell adhesions that shape tumor progression, invasiveness and 
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sensitivity to therapeutic agents (56)(57). Chronic hypoxia triggers the transcriptional upregulation of 
Cav3.2 channels in several cell types, mediated by hypoxia inducible factors (HIFs) (58)(59). Thus, the TTCC 
gene signature in cancer cells is likely to depend on O2 availability and HIFs activity. Intriguingly, the 
connection between TTCC and HIFs appears to be bidirectional: exposure to mibefradil reduced hypoxia-
induced HIF1α and HIF2 in GSC (20). Furthermore, TTCC blockade using different pharmacological agents, 
or Cav3.2 silencing, resulted in a reduced stability of HIF1 protein and expression of Vascular Endothelial 
Growth Factor (VEGF), ultimately inhibiting GBM-induced angiogenesis (60).  
Pioneer studies by Jung and colleagues evaluated the antitumor activity of KYS05090 in a mouse lung 
adenocarcinoma A549 xenograft, which slowed down tumor growth upon intravenous (61) or oral 
administration (62). Another 3,4-dihydroquinazoline able to block TTCC, KYS05047, demonstrated 
antitumor efficacy in the same xenograft model when administered orally (63). 
Other groups studied the effect of mibefradil or NNC-55-096 against solid tumors growing in vivo. In a 
xenograft model of ovarian cancer, HO8910 cells developed smaller tumors when co-injected with NNC-55-
096 (26). A similar approach was performed on a U87 GBM xenograft model (60). In consonance with in 
vitro results, intraperitoneal injection of NNC-55-0396 delayed tumor growth by inhibiting angiogenesis 
with a concomitant reduction of angiogenetic regulators (such as HIF-1, VEGF and Platelet-endothelial cell 
adhesion molecule).  
More elaborated protocols of mibefradil administration have been performed against diverse 
subcutaneous and intracranial GBM xenografts. Keir et al. designed a chemotherapeutic strategy in which 
mibefradil was first administered in order to synchronize GBM cell cycle at the G1/S boundary, then 
withdrawn followed by administration of alkylating agent temozolomide (64). The rationale behind this 
approach, termed interlaced therapy, was that mibefradil exposure would reduce the time for DNA repair 
systems to act against temozolomide-induced damage. Indeed, this combined therapy enhanced the 
efficacy of best single treatment (temozolomide), increasing overall survival by 18-68% depending on 
tumor types, implant location and treatment schedule.  
In addition, TTCC pharmacological blockade might synergize with radiotherapy, a common therapeutic tool 
for GBM. A study on rats carrying intracranial C6 glioma implants, showed that intraperitoneal injection of 
mibefradil and simultaneous radiosurgery slowed tumor growth and extended median survival from 35 
(radiosurgery alone) to 43 days. The benefits of initiating mibefradil treatment 1 week prior to 
radiotherapy were even stronger, achieving 52 days of median survival (65). These results suggest that the 
response to mibefradil in conjunction with ionizing radiation is also schedule-dependent.  
9 
 
Recently, administration of mibefradil inhibited the growth of GSC-derived intracranially-implanted GBM 
murine xenografts, and sensitized tumors to temozolomide treatment (20). In this study, two cycles of 
mibefradil (oral) and/or temozolomide (intraperitoneal) were concurrently administered. IHC revealed that 
proliferation marker Ki67 and stem cell marker SOX2 decreased, whereas astrocyte marker GFAP and 
caspase 3 increased in mibefradil-treated tumors. Data also showed that single treatments inhibited tumor 
growth by a similar magnitude, and that the combined treatment inhibited tumor growth in an additive 
fashion. Consistently, both mibefradil and temozolomide alone significantly prolonged animal survival, 
which was further extended with the combined treatment.  
 
Clinical trials: 
Early results attained in murine xenografts encouraged the enrollment of high-grade GBM patients in 
clinical trials in which TTCC are pharmacologically targeted with mibefradil, a drug with a well-known 
pharmacokinetic and toxicity profile (66). Cavion Pharma LLC (formerly Tau Therapeutics LLC), a 
pharmaceutical company focused on drug development and on the repurposing of mibefradil for oncology 
and neurological disease, performed in 2012 a dose escalation study to assess the safety of mibefradil 
dihydrochloride in 30 healthy patients, which rendered only mild and self-limited adverse effects 
(NCT01550458). This was followed by the launch of a second phase I study, in conjunction with the 
National Cancer Institute, to assess the efficiency and optimal dosage of mibefradil sequentially 
administered in combination with temozolomide in patients with recurrent GBM (NCT01480050). The 
results for this trial indicate that the therapy was generally well tolerated (67). A third trial sponsored by 
the same company in collaboration with Yale University has also been conducted (NCT02202993, 2014-
2017). This was a dose-escalation study to determine the safety and the maximum tolerated dose of 
mibefradil combined with hypofractionated radiation in patients with recurrent GBM, with no results 
published to date. 
 
Conclusion: 
Pharmacological blockade of TTCC reduces the viability of cancer cells in vitro and tumor growth in vivo. 
Preclinical results spearheaded the first clinical trials employing mibefradil in combined therapies against 
GBM. Yet, a compelling evaluation of TTCC as prognosis markers and/or targetable proteins in cancer will 
require a comprehensive characterization of the TTCC molecular signature, and a deeper knowledge of the 
cell signaling pathways stemming from TTCC activation/inhibition. Individual TTCC isoforms play different 
roles in cancer pathophysiology, but this notion is hampered by the absence of selective pharmacological 
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modulators. The expression of Cav3.1, which showed a positive correlation with autophagy markers, is 
predominant in some cancer types, while epigenetically silenced in others. The expression of Cav3.2, which 
increases in hypoxic conditions, has been associated to cancer stemness, aggressiveness and metastasis. 
The expression of Cav3.3 across cancer tissues remains largely unexplored, in spite of current evidences for 
a negative correlation with survival of gastric, lung and ovarian cancer patients. In addition to cancer, TTCC 
are currently under the scope of different biomedical fields, including neurological and cardiovascular 
disease. Multidisciplinary research efforts are bound to facilitate the development of isoform-specific tools, 
and will hopefully galvanize fine-tuned approaches for different cancer types and stages.  
 
Acknowledgements 
We apologize to all colleagues whose contributions are not cited here due to space limitations. 
 
Grant support  
Research in our lab is funded by Instituto de Salud Carlos III/FEDER “Una manera de hacer Europa” (grant 
PI13/01980 to JH). 
 
References 
 
1.  Hagiwara S, Ozawa S, Sand O. Voltage clamp analysis of two inward current mechanisms in the 
egg cell membrane of a starfish. J Gen Physiol. 1975;65:617–44.  
2.  Perez-Reyes E, Cribbs LL, Daud A, Lacerda AE, Barclay J, Williamson MP, et al. Molecular 
characterization of a neuronal low-voltage-activated T-type calcium channel. Nature [Internet]. 
1998 [cited 2017 Mar 22];391:896–900. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/9495342 
3.  Ertel EA, Campbell KP, Harpold MM, Hofmann F, Mori Y, Perez-Reyes E, et al. Nomenclature of 
voltage-gated calcium channels. Neuron. 2000;25:533–5.  
4.  Cribbs LL, Lee JH, Yang J, Satin J, Zhang Y, Daud A, et al. Cloning and characterization of alpha1H 
from human heart, a member of the T-type Ca2+ channel gene family. Circ Res [Internet]. 1998 
[cited 2017 Mar 22];83:103–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9670923 
5.  Lee JH, Daud AN, Cribbs LL, Lacerda AE, Pereverzev A, Klöckner U, et al. Cloning and expression of 
a novel member of the low voltage-activated T-type calcium channel family. J Neurosci [Internet]. 
1999 [cited 2017 Mar 22];19:1912–21. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10066244 
6.  Nilius B. Possible functional significance of a novel type of cardiac Ca channel. Biomed Biochim 
Acta [Internet]. 1986 [cited 2017 Mar 22];45:K37-45. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/2430559 
7.  Jahnsen H, Llinás R. Ionic basis for the electro-responsiveness and oscillatory properties of 
guinea-pig thalamic neurones in vitro. J Physiol [Internet]. 1984 [cited 2017 Mar 21];349:227–47. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/6737293 
8.  Carbone E, Lux HD. A low voltage-activated calcium conductance in embryonic chick sensory 
neurons. Biophys J [Internet]. 1984 [cited 2017 Oct 18];46:413–8. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/6487739 
9.  Bourinet E, Francois A, Laffray S. T-type calcium channels in neuropathic pain. Pain [Internet]. 
2016 [cited 2017 Sep 19];157:S15–22. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26785151 
10.  Iftinca MC. Neuronal T-type calcium channels: what’s new? Iftinca: T-type channel regulation. J 
11 
 
Med Life [Internet]. 2011;4:126–38. Available from: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3124264&tool=pmcentrez&rendert
ype=abstract 
11.  Lory P, Bidaud I, Chemin J. T-type calcium channels in differentiation and proliferation. Cell 
Calcium [Internet]. 2006 [cited 2017 Sep 15];40:135–46. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/16797068 
12.  Gray LS, Schiff D, Macdonald TL. A model for the regulation of T-type Ca 2+ channels in 
proliferation: roles in stem cells and cancer. Expert Rev Anticancer Ther [Internet]. 2013;13:589–
95. Available from: http://www.tandfonline.com/doi/full/10.1586/era.13.34 
13.  Borowiec A-S, Bidaux G, Pigat N, Goffin V, Bernichtein S, Capiod T. Calcium channels, external 
calcium concentration and cell proliferation. Eur J Pharmacol [Internet]. 2014 [cited 2017 Mar 
22];739:19–25. Available from: http://linkinghub.elsevier.com/retrieve/pii/S001429991300887X 
14.  Henley SA, Dick FA. The retinoblastoma family of proteins and their regulatory functions in the 
mammalian cell division cycle. Cell Div [Internet]. 2012 [cited 2017 Jul 7];7:10. Available from: 
http://celldiv.biomedcentral.com/articles/10.1186/1747-1028-7-10 
15.  Capiod T. Cell proliferation, calcium influx and calcium channels. Biochimie [Internet]. Elsevier 
Masson SAS; 2011;93:2075–9. Available from: http://dx.doi.org/10.1016/j.biochi.2011.07.015 
16.  Crunelli V, Tóth TI, Cope DW, Blethyn K, Hughes SW. The “window” T-type calcium current in 
brain dynamics of different behavioural states. J Physiol. 2005;562:121–9.  
17.  Blackiston DJ, McLaughlin KA, Levin M. Bioelectric controls of cell proliferation: Ion channels, 
membrane voltage and the cell cycle. Cell Cycle [Internet]. 2009 [cited 2017 Mar 23];8:3527–36. 
Available from: http://www.ncbi.nlm.nih.gov/pubmed/19823012 
18.  Welsby PJ, Wang H, Wolfe JT, Colbran RJ, Johnson ML, Barrett PQ. A mechanism for the direct 
regulation of T-type calcium channels by Ca2+/calmodulin-dependent kinase II. J Neurosci 
[Internet]. 2003 [cited 2017 Apr 11];23:10116–21. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/14602827 
19.  Choi J, Park J-H, Kwon OY, Kim S, Chung JH, Lim DS, et al. T-type calcium channel trigger p21ras 
signaling pathway to ERK in Cav3.1-expressed HEK293 cells. Brain Res [Internet]. 2005 [cited 2017 
Apr 4];1054:22–9. Available from: 
http://www.sciencedirect.com/science/article/pii/S0006899305007213 
20.  Zhang Y, Cruickshanks N, Yuan F, Wang B, Pahuski M, Wulfkuhle J, et al. Targetable T-type 
calcium channels drive glioblastoma. Cancer Res [Internet]. 2017;45209:canres.2347.2016. 
Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-16-2347 
21.  Huang CH, Chen YC, Chen C-CC, Hsu S-C, Chang Y-T, Chen C-CC, et al. Physical interaction 
between calcineurin and Cav3.2 T-type Ca 2+ channel modulates their functions. FEBS Lett 
[Internet]. Federation of European Biochemical Societies; 2013;587:1723–30. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/23929524 
22.  Lin S-S, Tzeng B-H, Lee K-R, Smith RJH, Campbell KP, Chen C-C. Cav3.2 T-type calcium channel is 
required for the NFAT-dependent Sox9 expression in tracheal cartilage. Proc Natl Acad Sci 
[Internet]. 2014 [cited 2017 Mar 31];111:E1990–8. Available from: 
http://www.pnas.org/cgi/doi/10.1073/pnas.1323112111 
23.  Wang H, Zhang X, Xue L, Xing J, Jouvin M-H, Putney JW, et al. Low-Voltage-Activated Ca V 3.1 
Calcium Channels Shape T Helper Cell Cytokine Profiles. Immunity [Internet]. 2016 [cited 2017 Jul 
21];44:782–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27037192 
24.  Monteith GR, Prevarskaya N, Roberts-Thomson SJ. The calcium–cancer signalling nexus. Nat Rev 
Cancer [Internet]. Nature Publishing Group; 2017; Available from: 
http://www.nature.com/doifinder/10.1038/nrc.2017.18 
25.  Büsselberg D, Florea A-M. Targeting Intracellular Calcium Signaling ([Ca 2+ ] i ) to Overcome 
Acquired Multidrug Resistance of Cancer Cells: A Mini-Overview. 2017;  
26.  Li W, Zhang S-L, Wang N, Zhang B-B, Li M. Blockade of T-type Ca(2+) channels inhibits human 
ovarian cancer cell proliferation. Cancer Invest. 2011;29:339–46.  
27.  Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based 
12 
 
map of the human proteome. Science (80- ) [Internet]. 2015 [cited 2017 Sep 12];347:1260419–
1260419. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25613900 
28.  Maiques O, Macià A, Moreno S, Barceló C, Santacana M, Vea A, et al. Immunohistochemical 
analysis of T-type calcium channels in acquired melanocytic naevi and melanoma. Br J Dermatol 
[Internet]. 2017 [cited 2017 Jun 6];176:1247–58. Available from: 
http://doi.wiley.com/10.1111/bjd.15121 
29.  Rodríguez-Gómez J a, Levitsky KL, López-Barneo J. T-type Ca2+ channels in mouse embryonic 
stem cells: modulation during cell cycle and contribution to self-renewal. Am J Physiol Cell Physiol 
[Internet]. 2012;302:C494-504. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22049210 
30.  Niklasson M, Maddalo G, Sramkova Z, Mutlu E, Wee S, Sekyrova P, et al. Membrane-depolarizing 
channel blockers induce selective glioma cell death by impairing nutrient transport and unfolded 
protein/amino acid responses. Cancer Res [Internet]. 2017 [cited 2017 Mar 23]; Available from: 
http://cancerres.aacrjournals.org/lookup/doi/10.1158/0008-5472.CAN-16-2274 
31.  Phan N, Wang C, Chen C, Sun Z, Lai M, Lin Y. Voltage-gated calcium channels: Novel targets for 
cancer therapy. Oncol Lett [Internet]. 2017;2059–74. Available from: http://www.spandidos-
publications.com/10.3892/ol.2017.6457 
32.  Fornaro L, Vivaldi C, Lin D, Xue H, Falcone A, Wang Y, et al. Prognostic relevance of a T-type 
calcium channels gene signature in solid tumours: A correlation ready for clinical validation. 
Lafrenie RM, editor. PLoS One [Internet]. Public Library of Science; 2017 [cited 2017 Aug 
31];12:e0182818. Available from: http://dx.plos.org/10.1371/journal.pone.0182818 
33.  Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in 
pancreatic adenocarcinoma. Cancer Res [Internet]. 2000 [cited 2017 Jun 8];60:1835–9. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/10766168 
34.  Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, et al. DNA methylation and 
environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst [Internet]. 2002 
[cited 2017 Jun 8];94:755–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12011226 
35.  Toyota M, Ho C, Ohe-Toyota M, Baylin SB, Issa JP. Inactivation of CACNA1G, a T-type calcium 
channel gene, by aberrant methylation of its 5’ CpG island in human tumors. Cancer Res 
[Internet]. 1999 [cited 2017 Jun 8];59:4535–41. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/10493502 
36.  Ouadid-Ahidouch H, Rodat-Despoix L, Matifat F, Morin G, Ahidouch A. DNA methylation of 
channel-related genes in cancers. Biochim Biophys Acta - Biomembr [Internet]. Elsevier B.V.; 
2015;1848:2621–8. Available from: http://dx.doi.org/10.1016/j.bbamem.2015.02.015 
37.  Hirooka K, Bertolesi GE, Kelly MEM, Denovan-Wright EM, Sun X, Hamid J, et al. T-Type calcium 
channel alpha1G and alpha1H subunits in human retinoblastoma cells and their loss after 
differentiation. J Neurophysiol [Internet]. 2002 [cited 2017 Mar 23];88:196–205. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/12091545 
38.  Dziegielewska B, Gray LS, Dziegielewski J. T-type calcium channels blockers as new tools in cancer 
therapies. Pflugers Arch Eur J Physiol. 2014;466:801–10.  
39.  Lu F, Chen H, Zhou C, Liu S, Guo M. T-type Ca 2+ channel expression in human esophageal 
carcinomas: A functional role in proliferation. Cell Calcium [Internet]. 2008;43:49–58. Available 
from: http://www.sciencedirect.com/science/article/pii/S014341600700070X 
40.  Dziegielewska B, Brautigan DL, Larner JM, Dziegielewski J. T-Type Ca 2þ Channel Inhibition 
Induces p53-Dependent Cell Growth Arrest and Apoptosis through Activation of p38-MAPK in 
Colon Cancer Cells. [cited 2017 Apr 11]; Available from: 
http://mcr.aacrjournals.org/content/molcanres/12/3/348.full.pdf 
41.  Tee A, Liu P, Marshall G, Liu T. Neuroblastoma: A Malignancy Due to Cell Differentiation Block. 
CdnIntechopenCom [Internet]. 2005;3. Available from: 
http://cdn.intechopen.com/pdfs/27475/InTech-
Neuroblastoma_a_malignancy_due_to_cell_differentiation_block.pdf 
42.  Chemin J, Nargeot J, Lory P. Neuronal T-type alpha 1H calcium channels induce neuritogenesis 
and expression of high-voltage-activated calcium channels in the NG108-15 cell line. J Neurosci. 
13 
 
2002;22:6856–62.  
43.  Tarui T, Fukami K, Nagasawa K, Yoshida S, Sekiguchi F, Kawabata A. Involvement of Src kinase in 
T-type calcium channel-dependent neuronal differentiation of NG108-15 cells by hydrogen 
sulfide. J Neurochem [Internet]. Blackwell Publishing Ltd; 2010 [cited 2017 Mar 28];114:512–9. 
Available from: http://doi.wiley.com/10.1111/j.1471-4159.2010.06774.x 
44.  Chemin J, Nargeot J, Lory P. Ca(v)3.2 calcium channels control an autocrine mechanism that 
promotes neuroblastoma cell differentiation. Neuroreport [Internet]. 2004 [cited 2017 Mar 
30];15:671–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15094473 
45.  Mariot P, Vanoverberghe K, Lalevee N, Rossier MF, Prevarskaya N. Overexpression of an  1H 
(Cav3.2) T-type Calcium Channel during Neuroendocrine Differentiation of Human Prostate 
Cancer Cells. J Biol Chem [Internet]. 2002 [cited 2017 Mar 31];277:10824–33. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/11799114 
46.  Weaver EM, Zamora FJ, Puplampu-Dove YA, Kiessu E, Hearne JL, Martin-Caraballo M. Regulation 
of T-type calcium channel expression by sodium butyrate in prostate cancer cells. Eur J 
Pharmacol [Internet]. 2015 [cited 2017 May 30];749:20–31. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25557765 
47.  Weaver EM, Zamora FJ, Hearne JL, Martin-Caraballo M. Posttranscriptional regulation of T-type 
Ca2+ channel expression by interleukin-6 in prostate cancer cells. Cytokine [Internet]. Elsevier 
Ltd; 2015;76:309–20. Available from: http://dx.doi.org/10.1016/j.cyto.2015.07.004 
48.  Sagnak L, Topaloglu H, Ozok U, Ersoy H. Prognostic Significance of Neuroendocrine 
Differentiation in Prostate Adenocarcinoma. Clin Genitourin Cancer [Internet]. 2011 [cited 2017 
Jun 1];9:73–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22035833 
49.  Das A, Pushparaj C, Herreros J, Nager M, Vilella R, Portero M, et al. T-type calcium channel 
blockers inhibit autophagy and promote apoptosis of malignant melanoma cells. Pigment Cell 
Melanoma Res. 2013;26:874–85.  
50.  Huang W, Lu C, Wu Y, Ouyang S, Chen Y. T-type calcium channel antagonists, mibefradil and NNC-
55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines. J Exp Clin Cancer 
Res [Internet]. ???; 2015;34:27–35. Available from: ??? 
51.  White E, Mehnert JM, Chan CS. Autophagy, Metabolism, and Cancer. Clin Cancer Res [Internet]. 
2015 [cited 2017 Sep 6];21:5037–46. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26567363 
52.  Rim H-K, Cho S, Shin D-H, Chung K-S, Cho Y-W, Choi J-H, et al. T-type Ca2+ channel blocker, 
KYS05090 induces autophagy and apoptosis in A549 cells through inhibiting glucose uptakeT-type 
Ca2+ channel blocker, KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular 
Ca2+ levels in human lung adenocarci. Molecules [Internet]. Elsevier Ltd; 2014;19:9864–75. 
Available from: http://dx.doi.org/10.1016/j.bmcl.2012.09.076 
53.  Koga H, Kaushik S, Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion. FASEB J 
[Internet]. 2010 [cited 2017 Jun 5];24:3052–65. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20375270 
54.  Valerie NCK, Dziegielewska B, Hosing AS, Augustin E, Gray LS, Brautigan DL, et al. Inhibition of T-
type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells. 
Biochem Pharmacol [Internet]. 2013 [cited 2017 Apr 28];85:888–97. Available from: 
http://www.sciencedirect.com/science/article/pii/S0006295212008258 
55.  Dziegielewska B, Casarez E V, Yang WZ, Gray LS, Dziegielewski J, Slack-Davis JK. T-Type Ca2+ 
Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin. Mol Cancer Ther [Internet]. NIH 
Public Access; 2016 [cited 2017 Jun 6];15:460–70. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/26832797 
56.  Ekert JE, Johnson K, Strake B, Pardinas J, Jarantow S, Perkinson R, et al. Three-dimensional lung 
tumor microenvironment modulates therapeutic compound responsiveness in vitro - Implication 
for drug development. PLoS One. 2014;9:1–14.  
57.  Chen J, Wang J, Zhang Y, Chen D, Yang C, Kai C, et al. Observation of ovarian cancer stem cell 
behavior and investigation of potential mechanisms of drug resistance in three-dimensional cell 
14 
 
culture. J Biosci Bioeng [Internet]. Elsevier Ltd; 2014;118:214–22. Available from: 
http://dx.doi.org/10.1016/j.jbiosc.2014.01.008 
58.  Sellak H, Zhou C, Liu B, Chen H, Lincoln TM, Wu S. Transcriptional regulation of α1H T-type 
calcium channel under hypoxia. Am J Physiol Cell Physiol [Internet]. American Physiological 
Society; 2014 [cited 2017 Sep 1];307:C648-56. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25099734 
59.  González-Rodríguez P, Falcón D, Castro MJ, Ureña J, López-Barneo J, Castellano A. Hypoxic 
induction of T-type Ca(2+) channels in rat cardiac myocytes: role of HIF-1α and RhoA/ROCK 
signalling. J Physiol [Internet]. Wiley-Blackwell; 2015 [cited 2017 Sep 1];593:4729–45. Available 
from: http://www.ncbi.nlm.nih.gov/pubmed/26331302 
60.  Kim KH, Kim D, Park JY, Jung HJ, Cho Y-H, Kim HK, et al. NNC 55-0396, a T-type Ca2+ channel 
inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction. 
J Mol Med [Internet]. 2015 [cited 2017 Sep 4];93:499–509. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/25471482 
61.  Jung SY, Lee SH, Kang HB, Park HA, Chang SK, Kim J, et al. Antitumor activity of 3,4-
dihydroquinazoline dihydrochloride in A549 xenograft nude mice. Bioorg Med Chem Lett 
[Internet]. 2010 [cited 2017 Jun 8];20:6633–6. Available from: 
http://www.ncbi.nlm.nih.gov/pubmed/20884207 
62.  Kang HB, Rim HK, Park JY, Choi HW, Choi DL, Seo JH, et al. In vivo evaluation of oral anti-tumoral 
effect of 3,4-dihydroquinazoline derivative on solid tumor. Bioorganic Med Chem Lett [Internet]. 
Elsevier Ltd; 2012;22:1198–201. Available from: http://dx.doi.org/10.1016/j.bmcl.2011.11.083 
63.  Rim H-K, Lee H-W, Choi IS, Park JY, Choi HW, Choi J-H, et al. T-type Ca2+ channel blocker, 
KYS05047 induces G1 phase cell cycle arrest by decreasing intracellular Ca2+ levels in human lung 
adenocarcinoma A549 cells. Bioorg Med Chem Lett [Internet]. 2012 [cited 2017 Jun 8];22:7123–
6. Available from: http://linkinghub.elsevier.com/retrieve/pii/S0960894X12012310 
64.  Keir ST, Friedman HS, Reardon DA, Bigner DD, Gray LA. Mibefradil, a novel therapy for 
glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model. J 
Neurooncol [Internet]. 2013 [cited 2017 Jun 9];111:97–102. Available from: 
http://link.springer.com/10.1007/s11060-012-0995-0 
65.  Sheehan JP, Xu Z, Popp B, Kowalski L, Schlesinger D. Inhibition of glioblastoma and enhancement 
of survival via the use of mibefradil in conjunction with radiosurgery. J Neurosurg [Internet]. 
2013;118:830–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23198803 
66.  Krouse AJ, Gray L, Macdonald T, McCray J. Repurposing and Rescuing of Mibefradil, an 
Antihypertensive, for Cancer: A Case Study. Assay Drug Dev Technol [Internet]. 2015;13:650–3. 
Available from: http://online.liebertpub.com/doi/full/10.1089/adt.2015.29014.ajkdrrr 
67.  Holdhoff M, Ye X, Supko JG, Nabors LB, Desai AS, Walbert T, et al. Timed sequential therapy of 
the selective T-type calcium channel blocker mibefradil and temozolomide in patients with 
recurrent high-grade gliomas. Neuro Oncol [Internet]. 2017;1–8. Available from: 
https://academic.oup.com/neuro-oncology/article-lookup/doi/10.1093/neuonc/nox020 
 
 
 
 
 
 
 
15 
 
Table 1: TTCC signature and value as prognostic markers in cancer 
TTCC 
isoform 
Tumor type Prognostic Expression level  
 
Assay References 
Cav3.1 
 
ovarian n.d. increased protein * IHC 26 
Cav3.2 
 
ovarian n.d. increased protein * IHC 26 
Cav3.1 
 
GBM (82% samples),  prostate (75% samples) 
 
n.d. n.d. IHC 27 
Cav3.2 GBM (27% samples), prostate (100% samples) n.d. n.d. IHC 27 
Cav3.1 
 
melanoma negative increased protein * IHC 28 
Cav3.2 
 
melanoma negative increased protein  *, ** IHC 28 
Cav3.2 subset of GBM enriched in GSC negative increased mRNA*and 
increased protein* 
RT-PCR and 
WB 
20 
 
Cav3.1 
sarcoma, lung, uterine, prostate, breast carcinoma, rectosigmoid carcinoma 
 
ovarian, renal, brain, bladder, mantel  cell lymphoma, colorectal carcinoma 
 
n.d. 
increased mRNA* 
 
decreased mRNA* 
MA,  
Oncomine database 
 
31 
 
Cav3.2 
renal, sarcoma, gastrointestinal stroma 
 
brain, ovarian, bladder, breast 
 
n.d.  
increased mRNA* 
 
decreased mRNA* 
MA,  
Oncomine database 
31 
 
Cav3.3 
breast, liposarcoma, esophageal adenocarcinoma 
 
GBM, anaplastic oligondendroglioma 
 
n.d. 
increased mRNA* 
 
decreased mRNA* 
MA, 
Oncomine database 
31 
Cav3.1 
 
gastric, lung 
ovarian 
positive 
negative 
n.d. MA, Kaplan- 
Meier database 
32 
Cav3.2 gastric, lung 
ovarian 
negative 
positive 
n.d. MA, Kaplan- 
Meier database 
32 
Cav3.3 gastric, lung ,ovarian negative 
 
n.d. MA, Kaplan- 
Meier database 
32 
Cav3.1 pancreatic, hepatic, gastric, colorectal, acute myelogenous leukemia  
(18-35% samples) 
n.d. hypermethylation  MSP 33-36 
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*relative to untransformed tissue; ** metastatic vs. primary tumors 
MA: microarray analysis; WB: Western blot; MSP: methylation-specific PCR 
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Legend to Figure 1 
TTCC form functional complexes with K(Ca2+) channels in the plasma membrane and trigger signaling 
pathways that may favor cell cycle progression or differentiation, depending on cell type and context. The 
figure combines a selection of relationships identified in different studies for TTCC-mediated signaling 
(green arrows) and effects of TTCC inhibition (red crosses/arrows), including activation of Cyclin/CDK 
complexes and CaM-dependent phosphorylation/dephosphorylation events. Arrow tips indicate whether 
the modulation is positive (pointed) or negative (round). Dashed lines indicate ion fluxes/transport across 
the plasma membrane.   
 
Legend to Figure 2  
TTCC-mediated signaling (green arrows) and effects of TTCC inhibition (red crosses/arrows) on cell 
survival/apoptosis. The figure combines a selection of relationships identified in different studies. Arrow 
tips indicate whether the modulation is positive (pointed) or negative (round). TTCC inhibition may induce 
apoptosis by PKB/Akt dephosphorylation or by activation of the p38-MAPK-p53 axis. TTCC/K(Ca2+) blockade 
may also cause plasma membrane depolarization and compromise Na+-dependent nutrient transport, in 
turn inducing the unfolded protein response (UPR) and the amino acid response (AAR), which may convey 
into apoptosis or autophagy. A question mark ‘?’ indicates that the contribution of TTCC to these Ca2+-
dependent processes is speculative.  
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